Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective
Invasive fungal infections cause significant morbidity and mortality in patients with concomitant underlying immunosuppressive diseases. The recent addition of new triazoles to the antifungal armamentarium has allowed for extended-spectrum activity and flexibility of administration. Over the years,...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2014/340586 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553979084537856 |
|---|---|
| author | Michel Laverdiere Eric J Bow Coleman Rotstein Julie Autmizguine Raewyn Broady Gary Garber Shariq Haider Trana Hussaini Shahid Husain Philippe Ovetchkine Jack T Seki Yves Théorêt |
| author_facet | Michel Laverdiere Eric J Bow Coleman Rotstein Julie Autmizguine Raewyn Broady Gary Garber Shariq Haider Trana Hussaini Shahid Husain Philippe Ovetchkine Jack T Seki Yves Théorêt |
| author_sort | Michel Laverdiere |
| collection | DOAJ |
| description | Invasive fungal infections cause significant morbidity and mortality in patients with concomitant underlying immunosuppressive diseases. The recent addition of new triazoles to the antifungal armamentarium has allowed for extended-spectrum activity and flexibility of administration. Over the years, clinical use has raised concerns about the degree of drug exposure following standard approved drug dosing, questioning the need for therapeutic drug monitoring (TDM). Accordingly, the present guidelines focus on TDM of triazole antifungal agents. A review of the rationale for triazole TDM, the targeted patient populations and available laboratory methods, as well as practical recommendations based on current evidence from an extended literature review are provided in the present document. |
| format | Article |
| id | doaj-art-e4c785a740f146b89bfa6f6ca87c510e |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-e4c785a740f146b89bfa6f6ca87c510e2025-02-03T05:52:50ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322014-01-0125632734310.1155/2014/340586Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveMichel Laverdiere0Eric J Bow1Coleman Rotstein2Julie Autmizguine3Raewyn Broady4Gary Garber5Shariq Haider6Trana Hussaini7Shahid Husain8Philippe Ovetchkine9Jack T Seki10Yves Théorêt11Department of Microbiology and Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, CanadaDepartments of Medical Microbiology and Infectious Diseases, and Internal Medicine, Sections of Infectious Diseases and Hematology∕Oncology, Blood and Marrow Transplant, University of Manitoba, Winnipeg, Manitoba, CanadaDivision of Infectious Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, CanadaService des Maladies Infectieuses, Département de Pédiatrie, CanadaDivision of Haematology, University of British Columbia, Vancouver, British Columbia, CanadaDivision of Infectious Diseases, University of Ottawa∕Ottawa Hospital, CanadaHamilton Health Sciences, McMaster University, Hamilton, Ontario, CanadaSolid Organ Transplantation, Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital, Vancouver, British Columbia, CanadaDivision of Infectious Diseases, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, CanadaService de Maladies Infectieuses, Département de Pédiatrie, CHU Sainte-Justine, Université de Montréal, Montreal, CanadaDepartment of Pharmacy, Princess Margaret Cancer Centre, University Health Network, CanadaUnité de Pharmacologie Clinique, CHU Ste-Justine, Montreal, Quebec, CanadaInvasive fungal infections cause significant morbidity and mortality in patients with concomitant underlying immunosuppressive diseases. The recent addition of new triazoles to the antifungal armamentarium has allowed for extended-spectrum activity and flexibility of administration. Over the years, clinical use has raised concerns about the degree of drug exposure following standard approved drug dosing, questioning the need for therapeutic drug monitoring (TDM). Accordingly, the present guidelines focus on TDM of triazole antifungal agents. A review of the rationale for triazole TDM, the targeted patient populations and available laboratory methods, as well as practical recommendations based on current evidence from an extended literature review are provided in the present document.http://dx.doi.org/10.1155/2014/340586 |
| spellingShingle | Michel Laverdiere Eric J Bow Coleman Rotstein Julie Autmizguine Raewyn Broady Gary Garber Shariq Haider Trana Hussaini Shahid Husain Philippe Ovetchkine Jack T Seki Yves Théorêt Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| title_full | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| title_fullStr | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| title_full_unstemmed | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| title_short | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| title_sort | therapeutic drug monitoring for triazoles a needs assessment review and recommendations from a canadian perspective |
| url | http://dx.doi.org/10.1155/2014/340586 |
| work_keys_str_mv | AT michellaverdiere therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT ericjbow therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT colemanrotstein therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT julieautmizguine therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT raewynbroady therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT garygarber therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT shariqhaider therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT tranahussaini therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT shahidhusain therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT philippeovetchkine therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT jacktseki therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective AT yvestheoret therapeuticdrugmonitoringfortriazolesaneedsassessmentreviewandrecommendationsfromacanadianperspective |